Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPG PRP is an autologous platelet-rich plasma (PRP) therapy medical device developed by Dermoaroma for aesthetic and cosmetic treatments, particularly skin rejuvenation. The system is a Class IIb medical device that is CE-marked and FDA validated, designed to prepare and administer autologous platelet concentrates enriched with growth factors and cytokines. The process involves drawing the patient's blood into sterile vacuum tubes, centrifuging it to concentrate platelets, and activating them (typically with Calcium Chloride or Batroxobin) before injection into the treatment area. The resulting PRP contains high concentrations of growth factors, such as PDGF, TGF-beta, and VEGF, which stimulate cellular regeneration, collagen synthesis, and tissue repair. Clinically, it is used to eliminate wrinkles, restore facial volume, improve the appearance of acne scars, and accelerate healing following facial peels, offering a non-invasive, biocompatible alternative to synthetic fillers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DPG PRP.